| DegludecPlus (insulin degludec/insulin aspart) / Novo Nordisk |
| Active, not recruiting | 3 | 200 | Europe, Canada, Japan, US, RoW | Somapacitan, Norditropin® | Novo Nordisk A/S | Growth Hormone Deficiency in Children | 11/21 | 09/25 | | |
ChiCTR2400081416: Efficacy and Safety of Insulin Degludec/Insulin Aspart Injection in Chinese Patients with Type 2 Diabetes: A Multicenter, Randomized, Open-label, Parallel-group, Positive-controlled, Phase 3 Study |
|
|
| Completed | 3 | 358 | | Hui Sheng insulin degludec/insulin aspart injection, treatment for 24 weeks; Originator insulin degludec/insulin aspart injection (Ryzodeg), treatment for 24 weeks | Peking University People's Hospital; Hui Sheng Bio-pharmaceutical Co., Ltd., Sponsor | Type 2 Diabetes Mellitus | | | | |
NCT05413369: iGlarLixi vs IDegAsp in Chinese Participants After OAD(s) |
|
|
| Completed | 3 | 582 | RoW | Insulin glargine/Lixisenatide, IDegAsp, Metformin, SGLT2 inhibitor | Sanofi | Type 2 Diabetes Mellitus | 10/23 | 10/23 | | |
NCT05802862: A Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared With Insulin Degludec/Insulin Aspart(Ryzodeg) in Participants With Type 2 Diabetes in China |
|
|
| Not yet recruiting | 3 | 408 | NA | Insulin Degludec and Insulin Aspart | Sunshine Lake Pharma Co., Ltd. | Diabetes | 12/23 | 03/24 | | |
